Paris, 22nd September 2026 – AndzonBio2, a biotechnology company developing next-generation therapeutics for neuroinflammatory and neurodegenerative diseases, today announced the execution of agreements with Inserm Transfert and the launch of a strategic research collaboration with Inserm, the University of Lille…
Paris, France and Cambridge, UK, May 13, 2026 – AndzonBio2 today announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation,…
Paris, February 3, 2026 – AndzonBio2, a biotechnology company focused on developing innovative therapeutic programs in neuroinflammation, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading experts in neuroscience, neurodegeneration, drug discovery, and translational development. The…
Paris, France, October 23, 2025 – AndzonBio2 emerges from stealth mode and announces a €3M ($3.5M) seed funding from AdBio Partners, a venture capital company builder fund specialized in early-stage investments in life sciences, and Inserm Transfert, the private subsidiary…